These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

804 related articles for article (PubMed ID: 30882240)

  • 41. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial.
    Spertus JA; Birmingham MC; Nassif M; Damaraju CV; Abbate A; Butler J; Lanfear DE; Lingvay I; Kosiborod MN; Januzzi JL
    Nat Med; 2022 Apr; 28(4):809-813. PubMed ID: 35228753
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SGLT2 inhibitors: What role do they play in heart failure with reduced ejection fraction?
    Lenahan CM; Harrington D; Stueben F
    Nurse Pract; 2021 Jul; 46(7):30-37. PubMed ID: 34138811
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin.
    Polidori D; Iijima H; Goda M; Maruyama N; Inagaki N; Crawford PA
    Diabetes Obes Metab; 2018 May; 20(5):1321-1326. PubMed ID: 29341404
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Type 2 diabetes and heart failure: Characteristics and prognosis in preserved, mid-range and reduced ventricular function.
    Johansson I; Dahlström U; Edner M; Näsman P; Rydén L; Norhammar A
    Diab Vasc Dis Res; 2018 Nov; 15(6):494-503. PubMed ID: 30176743
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
    Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B
    Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
    Packer M
    Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).
    Jensen J; Omar M; Kistorp C; Poulsen MK; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Fosbøl E; Bruun NE; Videbæk L; Frederiksen PH; Møller JE; Schou M
    Trials; 2019 Jun; 20(1):374. PubMed ID: 31227014
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SCORED and SOLOIST: the next scores for SGLT2 inhibitors.
    Bauersachs J
    Cardiovasc Res; 2021 Mar; 117(4):e49-e51. PubMed ID: 33439963
    [No Abstract]   [Full Text] [Related]  

  • 49. Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure.
    Kasperova BJ; Mraz M; Svoboda P; Hlavacek D; Kratochvilova H; Modos I; Vrzackova N; Ivak P; Janovska P; Kobets T; Mahrik J; Riecan M; Steiner Mrazova L; Stranecky V; Netuka I; Cajka T; Kuda O; Melenovsky V; Stemberkova Hubackova S; Haluzik M
    Cardiovasc Diabetol; 2024 Jun; 23(1):223. PubMed ID: 38943140
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial.
    Tanaka A; Imai T; Shimabukuro M; Taguchi I; Sezai A; Toyoda S; Watada H; Ako J; Node K;
    Cardiovasc Diabetol; 2022 Aug; 21(1):151. PubMed ID: 35941584
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Case of Fournier's Gangrene in a Patient Taking Canagliflozin for the Treatment of Type II Diabetes Mellitus.
    Elbeddini A; Gallinger J; Davey M; Brassard S; Gazarin M; Plourde F; Aly A
    Am J Case Rep; 2020 Feb; 21():e920115. PubMed ID: 32089542
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors.
    Vaduganathan M; Januzzi JL
    Am J Cardiol; 2019 Dec; 124 Suppl 1():S20-S27. PubMed ID: 31741436
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Not Available].
    Shamchuk A; Doulla M; Jetha M
    CMAJ; 2021 Nov; 193(45):E1746-E1749. PubMed ID: 34782384
    [No Abstract]   [Full Text] [Related]  

  • 54. Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist.
    Bethel MA; McMurray JJV
    Circulation; 2018 Mar; 137(12):1218-1220. PubMed ID: 29555706
    [No Abstract]   [Full Text] [Related]  

  • 55. [In patients with type 2 diabetes and diabetic nephropathy with albuminuria, what is the effect of SGLT2 inhibitor canagliflozin on renal and cardiovascular outcomes?].
    Lanthier L; Huard G; Plourde MÉ; Cauchon M
    Rev Med Interne; 2020 Jan; 41(1):67-68. PubMed ID: 31812446
    [No Abstract]   [Full Text] [Related]  

  • 56. Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors.
    Evans M; Morgan AR; Yousef Z; Ellis G; Dashora U; Patel DC; Brown P; Hanif W; Townend JN; Kanumilli N; Moore J; Wilding JPH; Bain SC
    Drugs; 2021 Jul; 81(11):1243-1255. PubMed ID: 34160822
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis.
    Halabi A; Sen J; Huynh Q; Marwick TH
    Cardiovasc Diabetol; 2020 Aug; 19(1):124. PubMed ID: 32758236
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Great Debate: SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction.
    Packer M; Cleland JGF; Bauersachs J
    Eur Heart J; 2024 Jul; 45(25):2186-2196. PubMed ID: 38805680
    [No Abstract]   [Full Text] [Related]  

  • 59. Treating heart failure with preserved ejection fraction: statins could make the difference.
    Athyros VG; Katsiki N; Karagiannis A
    Angiology; 2014 Apr; 65(4):328-9. PubMed ID: 24202663
    [No Abstract]   [Full Text] [Related]  

  • 60. Do the Favorable Effects of Digoxin and SGLT2 Inhibitors Really Differ in Patients with Heart Failure and a Reduced Ejection Fraction? A Provocative Side-by-Side Examination of Trial Outcomes.
    Packer M; Zannad F
    J Card Fail; 2022 Apr; 28(4):682-683. PubMed ID: 35038597
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.